Cargando…
Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy
Background: Genetic variation near the interferon lambda 3 (IFNL3) is known to be associated with response to pegylated interferon (pegIFN) and ribavirin combination therapy in patients with chronic hepatitis C virus (HCV) infection which is often accompanied by hepatic steatosis. Aims: We examined...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666539/ https://www.ncbi.nlm.nih.gov/pubmed/29104462 http://dx.doi.org/10.7150/ijms.20171 |
_version_ | 1783275337684090880 |
---|---|
author | Nakamoto, Shingo Imazeki, Fumio Kanda, Tatsuo Wu, Shuang Nakamura, Masato Yasui, Shin Tawada, Akinobu Mikata, Rintaro Chiba, Tetsuhiro Arai, Makoto Yokosuka, Osamu Shirasawa, Hiroshi |
author_facet | Nakamoto, Shingo Imazeki, Fumio Kanda, Tatsuo Wu, Shuang Nakamura, Masato Yasui, Shin Tawada, Akinobu Mikata, Rintaro Chiba, Tetsuhiro Arai, Makoto Yokosuka, Osamu Shirasawa, Hiroshi |
author_sort | Nakamoto, Shingo |
collection | PubMed |
description | Background: Genetic variation near the interferon lambda 3 (IFNL3) is known to be associated with response to pegylated interferon (pegIFN) and ribavirin combination therapy in patients with chronic hepatitis C virus (HCV) infection which is often accompanied by hepatic steatosis. Aims: We examined whether this genetic variation is associated with host lipids and treatment response. Methods: A total of 101 Japanese patients who had underwent liver biopsy before treatment with pegIFN and ribavirin for HCV genotype 1b infection were retrospectively analyzed for association between IFNL3 genotypes (rs8099917) and clinical factors including histopathological features of the liver. The presence of >5% steatosis in the liver specimen was defined as hepatic steatosis. Results: Forty patients (40%) had liver steatosis before therapy. Patients with IFNL3 minor genotype (non-TT) showed lower low-density lipoprotein cholesterol level (p=0.0045), higher γ-glutamyl transpeptidase level (p=0.0003) and higher prevalence of hepatic steatosis (p=0.0002). Advanced fibrosis [odds ratio (OR) 4.63, p=0.03] and IFNL3 major genotype (OR 0.13, p=0.001) were 2 independent factors for determining the presence of hepatic steatosis. Among the factors associated with sustained virological response, IFNL3 genotype was the most significant predictor, as per multivariate analysis. Conclusions: Our results confirmed that IFNL3 genotype is associated with hepatic steatosis as well as IFN response. |
format | Online Article Text |
id | pubmed-5666539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-56665392017-11-04 Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy Nakamoto, Shingo Imazeki, Fumio Kanda, Tatsuo Wu, Shuang Nakamura, Masato Yasui, Shin Tawada, Akinobu Mikata, Rintaro Chiba, Tetsuhiro Arai, Makoto Yokosuka, Osamu Shirasawa, Hiroshi Int J Med Sci Research Paper Background: Genetic variation near the interferon lambda 3 (IFNL3) is known to be associated with response to pegylated interferon (pegIFN) and ribavirin combination therapy in patients with chronic hepatitis C virus (HCV) infection which is often accompanied by hepatic steatosis. Aims: We examined whether this genetic variation is associated with host lipids and treatment response. Methods: A total of 101 Japanese patients who had underwent liver biopsy before treatment with pegIFN and ribavirin for HCV genotype 1b infection were retrospectively analyzed for association between IFNL3 genotypes (rs8099917) and clinical factors including histopathological features of the liver. The presence of >5% steatosis in the liver specimen was defined as hepatic steatosis. Results: Forty patients (40%) had liver steatosis before therapy. Patients with IFNL3 minor genotype (non-TT) showed lower low-density lipoprotein cholesterol level (p=0.0045), higher γ-glutamyl transpeptidase level (p=0.0003) and higher prevalence of hepatic steatosis (p=0.0002). Advanced fibrosis [odds ratio (OR) 4.63, p=0.03] and IFNL3 major genotype (OR 0.13, p=0.001) were 2 independent factors for determining the presence of hepatic steatosis. Among the factors associated with sustained virological response, IFNL3 genotype was the most significant predictor, as per multivariate analysis. Conclusions: Our results confirmed that IFNL3 genotype is associated with hepatic steatosis as well as IFN response. Ivyspring International Publisher 2017-09-04 /pmc/articles/PMC5666539/ /pubmed/29104462 http://dx.doi.org/10.7150/ijms.20171 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Nakamoto, Shingo Imazeki, Fumio Kanda, Tatsuo Wu, Shuang Nakamura, Masato Yasui, Shin Tawada, Akinobu Mikata, Rintaro Chiba, Tetsuhiro Arai, Makoto Yokosuka, Osamu Shirasawa, Hiroshi Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy |
title | Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy |
title_full | Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy |
title_fullStr | Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy |
title_full_unstemmed | Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy |
title_short | Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy |
title_sort | association of ifnl3 genotype with hepatic steatosis in chronic hepatitis c patients treated with peginterferon and ribavirin combination therapy |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666539/ https://www.ncbi.nlm.nih.gov/pubmed/29104462 http://dx.doi.org/10.7150/ijms.20171 |
work_keys_str_mv | AT nakamotoshingo associationofifnl3genotypewithhepaticsteatosisinchronichepatitiscpatientstreatedwithpeginterferonandribavirincombinationtherapy AT imazekifumio associationofifnl3genotypewithhepaticsteatosisinchronichepatitiscpatientstreatedwithpeginterferonandribavirincombinationtherapy AT kandatatsuo associationofifnl3genotypewithhepaticsteatosisinchronichepatitiscpatientstreatedwithpeginterferonandribavirincombinationtherapy AT wushuang associationofifnl3genotypewithhepaticsteatosisinchronichepatitiscpatientstreatedwithpeginterferonandribavirincombinationtherapy AT nakamuramasato associationofifnl3genotypewithhepaticsteatosisinchronichepatitiscpatientstreatedwithpeginterferonandribavirincombinationtherapy AT yasuishin associationofifnl3genotypewithhepaticsteatosisinchronichepatitiscpatientstreatedwithpeginterferonandribavirincombinationtherapy AT tawadaakinobu associationofifnl3genotypewithhepaticsteatosisinchronichepatitiscpatientstreatedwithpeginterferonandribavirincombinationtherapy AT mikatarintaro associationofifnl3genotypewithhepaticsteatosisinchronichepatitiscpatientstreatedwithpeginterferonandribavirincombinationtherapy AT chibatetsuhiro associationofifnl3genotypewithhepaticsteatosisinchronichepatitiscpatientstreatedwithpeginterferonandribavirincombinationtherapy AT araimakoto associationofifnl3genotypewithhepaticsteatosisinchronichepatitiscpatientstreatedwithpeginterferonandribavirincombinationtherapy AT yokosukaosamu associationofifnl3genotypewithhepaticsteatosisinchronichepatitiscpatientstreatedwithpeginterferonandribavirincombinationtherapy AT shirasawahiroshi associationofifnl3genotypewithhepaticsteatosisinchronichepatitiscpatientstreatedwithpeginterferonandribavirincombinationtherapy |